ArticleJACC. Case reports2025
Relief of Refractory Angina With Vericiguat.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRefractory angina represents a challenging clinical symptom, with limited therapeutic options beyond conventional antianginal therapy and revascularization. CASE SUMMARY: A 43-year-old man with a history of hypertension, diabetes mellitus, and coronary atherosclerotic heart disease presented with persistent angina pectoris, classified as Canadian Cardiovascular Society class IV, despite being on optimized antianginal therapy including calcium-channel blockers, nitrates, and other adjunctive medications. His Seattle Angina Questionnaire score was 12.61. Introduction of vericiguat 10 mg daily resulted in marked symptom improvement, with Seattle Angina Questionnaire score increasing to 57.35 and angina classification improving to class II. DISCUSSION: This represents to our knowledge the first documented use of vericiguat for refractory angina. Vericiguat stimulates soluble guanylate cyclase and enhances cyclic GMP production, improving endothelial dysfunction and impaired vasodilation; this may be the mechanism by which it relieves refractory angina. TAKE-HOME MESSAGES: Vericiguat may offer therapeutic benefit in refractory angina patients unresponsive to conventional therapy. Further investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.